5/28/2020
Big gene therapy names line up behind experimental Covid-19 vaccine
An early stage vaccine against Covid-19 based on the same basic technology used in gene therapy is gaining some support from some of that field’s biggest names.
News
5/28/2020
Novartis Inks Deal to Make Experimental Coronavirus Vaccine
Swiss drugmaker will make gene-based Covid-19 vaccine being developed at Massachusetts Eye and Ear, Massachusetts General Hospital and University of Pennsylvania
5/12/2020
Passage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting
Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced the presentation of preclinical data for its Krabbe disease program. This data was presented today in a virtual oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 23rd Annual Meeting by Juliette Hordeaux, D.V.M., Ph.D., senior director of translational research at the University of Pennsylvania’s Gene Therapy Program.
5/08/2020
Million Dollar Bike Ride
7TH ANNUAL MILLION DOLLAR BIKE RIDE: June 13, 2020 NOW A VIRTUAL EVENT!
5/07/2020
Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania
We are thrilled that our collaboration with Passage Bio is expanding!
5/01/2020
Spotlight on the News: COVID-19, Albion Coll., ACLU MI.; James Wilson, Mauri Ditzler & Dan Korobkin
On Sunday, May 3, Spotlight on the News will focus on the race to find a vaccine to protect humans from the COVID-19 virus. Noted University of Pennsylvania scientist Dr. James M. Wilson grants Spotlight his first Detroit television interview on why his lab was picked to search for a cure. We'll also talk to Albion College President Mauri Ditzler about the school's Michigan Promise Scholarship Program and Albion's connection to Dr. Wilson. And how has the ACLU of Michigan been impacted by the Coronavirus? Legal Director Dan Korobkin will tell us.